Hormonal Therapy for Gynecological Cancers: How Far Has Science Progressed toward Clinical Applications?

Cancers

Trina Ekawati Tallei¹  M. Yasmin Begum²  Afaf Aldahish³  Kumarappan Chidambaram³  Talha Bin Emran⁴  Fahadul Islam⁵  Saikat Mitra⁶  Avoy Ghosh⁶  Rajib Das⁶  Mashia Subha Lami⁶  Kuldeep Dhama⁷  Fatimawali⁸ 

[1] Department of Biology, Faculty of Mathematics and Natural Sciences, Sam Ratulangi University, Manado 95115, Indonesia;Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha 61441, Saudi Arabia;Department of Pharmacology and Toxicology, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia;Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh;Department of Pharmacy, Faculty of Allied Health of Sciences, Daffodil International University, Dhaka 1207, Bangladesh;Department of Pharmacy, Faculty of Pharmacy, University of Dhaka, Dhaka 1000, Bangladesh;Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly 243122, Uttar Pradesh, India;The University Center of Excellence for Biotechnology and Conservation of Wallacea, Institute for Research and Community Services, Sam Ratulangi University, Manado 95115, Indonesia;

关键词: hormonal therapy;    gynecological cancers;    aromatase inhibitors;    anti-estrogen;    GnRH agonist;   

DOI  :  10.3390/cancers14030759

来源: DOAJ

【 摘 要 】

In recent years, hormone therapy has been shown to be a remarkable treatment option for cancer. Hormone treatment for gynecological cancers involves the use of medications that reduce the level of hormones or inhibit their biological activity, thereby stopping or slowing cancer growth. Hormone treatment works by preventing hormones from causing cancer cells to multiply. Aromatase inhibitors, anti-estrogens, progestin, estrogen receptor (ER) antagonists, GnRH agonists, and progestogen are effectively used as therapeutics for vulvar cancer, cervical cancer, vaginal cancer, uterine cancer, and ovarian cancer. Hormone replacement therapy has a high success rate. In particular, progestogen and estrogen replacement are associated with a decreased incidence of gynecological cancers in women infected with human papillomavirus (HPV). The activation of estrogen via the transcriptional functionality of ERα may either be promoted or decreased by gene products of HPV. Hormonal treatment is frequently administered to patients with hormone-sensitive recurring or metastatic gynecologic malignancies, although response rates and therapeutic outcomes are inconsistent. Therefore, this review outlines the use of hormonal therapy for gynecological cancers and identifies the current knowledge gaps.

【 授权许可】

Unknown